All Posts

Cureus published 13 March 2025 Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA) known for its glucose-lowering and...

BMC Pharmacology and Toxicology 26 (1) March 2025 Cefiderocol is a new drug class, which is approved to treat Gram-negative bacteria...

Businesswire 25 Feb 2025 Atropos Health, a pioneer in translating clinical data into personalized real-world evidence (RWE) and insights,...

University of Calgary 6 March 2025 An innovative data research program at the University of Calgary's Cumming School of Medicine (CSM)...

Nature : published 7 March 2025 Omalizumab is a biologic agent used in the management of allergic conditions, including asthma and...

By Target RWE 7 May 2025 Real-world evidence (RWE) leader, Target RWE, announced updates from its longitudinal dermatology study of more...

By ET Bureau 13 March 2025 OM1, a leading provider of real-world data (RWD) and AI-powered analytics for life sciences, today announced...

Nature: Published 6 March 2025 Artificial intelligence (AI) improves the accuracy of mammography screening, but prospective evidence,...

Nature: Published 11 March 2025 Adults with autism spectrum disorder (ASD) may compensate for their social difficulties by resorting to...

The way ahead for HEOR in biopharma should be built on increasing C-suite visibility and understanding of the value contribution that HEOR makes and demonstrating that a failure to invest in HEOR puts companies at a competitive disadvantage, especially in the face of rising regulatory and payer expectations for evidence.

Reading time: 5mins (full article) On July 25, 2024, the US Food and Drug Administration (FDA) announced the release of a final version...

CONTEXT:  Commercial announcement from Biodesix and Datavant to enhance their current lung cancer specific RWD biobank.  It is hoped that...

CONTEXT:  A very interesting opinion piece on the implications of the increased role of real-world evidence (RWE) in the pharmaceutical...